LAM
NEUP

Lewis Asset Management’s Neuphoria Therapeutics NEUP Stock Holding History

Lewis Asset Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,917
Closed -$17.6K – 135
2024
Q2 		$17.6K Buy
1,917
+667
+53% +$7.26K 0.01% 117
2024
Q1 		$15.4K Buy
+1,250
New +$16.5K 0.01% 117

Other funds holding NEUP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Lewis Asset Management's NEUP Position: Q3 2024 in Review

Lewis Asset Management sold out of Neuphoria Therapeutics (NEUP) in Q3 2024, closing a stake of 1,917 shares — an estimated $17.6K sold.

Lewis Asset Management first reported a position in NEUP in Q1 2024 and held it in 2 quarters. The position peaked at $17.6K in Q2 2024. 8 funds tracked by Wall St. Rank hold NEUP as of Q3 2024.

  • Lewis Asset Management reported no remaining Neuphoria Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Lewis Asset Management sold 1,917 Neuphoria Therapeutics shares in Q3 2024, an estimated $17.6K.
  • Lewis Asset Management first reported a position in Neuphoria Therapeutics in Q1 2024 and held it in 2 quarters.
  • Lewis Asset Management's Neuphoria Therapeutics position peaked at $17.6K in Q2 2024.
  • 8 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q3 2024.

Based on Lewis Asset Management's 13F filing for Q3 2024, filed 31 Oct 2024.